Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis

NCT00029042 is registered in ClinicalTrials.gov with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as lead sponsor.

NCT NCT00029042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00029042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2002
Completion date
October 31, 2005
Enrollment
48
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile rheumatoid arthritis